ERIS Lifesciences Ltd (ERIS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1002771,
    "name": "ERIS Lifescience",
    "stock_name": "ERIS Lifescience",
    "full_name": "ERIS Lifesciences Ltd",
    "name_url": "stocks-analysis/eris-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,433.00",
    "chg": 22.8,
    "chgp": "1.62%",
    "dir": 1,
    "prev_price": "1,410.20",
    "mcapval": "19,743.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 540596,
    "symbol": "ERIS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE406M01024",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "54.24 k",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/eris-lifescience-1002771-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ERIS Lifesciences Ltd Reports Strong Quarterly Upswing Amid Positive Financial Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-reports-strong-quarterly-upswing-amid-positive-financial-trend-4001995",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_fintrenddot_4001995.png",
        "date": "2026-05-21 08:00:20",
        "description": "ERIS Lifesciences Ltd has demonstrated a marked improvement in its financial performance for the quarter ended March 2026, signalling a positive shift in its financial trend after a period of stagnation. The company’s latest quarterly results reveal robust revenue growth, margin expansion, and significant profitability gains, positioning it favourably within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "ERIS Lifesciences Ltd Surges 8.32% to Day's High of Rs 1458 — Outperforms Sector by 8.15 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-hits-intraday-high-with-832-surge-on-20-may-2026-4001193",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_priceRelatedfactors_4001193.png",
        "date": "2026-05-20 15:01:22",
        "description": "The Sensex edged up 0.26% after a volatile session, but ERIS Lifesciences Ltd outpaced the broader market with an 8.32% gain, reaching an intraday high of Rs 1458. This 8.15-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-4000705",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_mojoScore_4000705.png",
        "date": "2026-05-20 10:10:56",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3982747",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_mojoScore_3982747.png",
        "date": "2026-05-09 10:10:36",
        "description": "ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Growing Price Pressure Amid Sector Comparisons",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-growing-price-pressure-amid-sector-comparisons-3974669",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_valuationdot_3974669.png",
        "date": "2026-05-05 08:01:25",
        "description": "ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change has prompted a downgrade in its Mojo Grade from Hold to Sell, signalling increased caution among investors despite the company’s solid operational metrics and long-term returns outperforming the Sensex."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-3967388",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ERISLifescience_valuationdot_3967388.png",
        "date": "2026-04-29 08:00:46",
        "description": "ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, signalling improved price attractiveness for investors. Despite recent headwinds reflected in its share price performance, the company’s relative valuation metrics now present a more balanced risk-reward profile compared to its pharmaceutical peers and historical averages."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3966332",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ERISLifescience_mojoScore_3966332.png",
        "date": "2026-04-28 10:10:55",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3960144",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ERISLifescience_technicaldot_3960144.png",
        "date": "2026-04-24 08:03:17",
        "description": "ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, as reflected in recent indicator readings. Despite a 3.07% gain on 24 Apr 2026, the stock’s technical parameters present a complex picture, with mixed signals from MACD, RSI, moving averages, and other key indicators, suggesting cautious optimism amid underlying challenges."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3950643",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ERISLifescience_mojoScore_3950643.png",
        "date": "2026-04-17 10:10:58",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      }
    ],
    "total": 15,
    "sid": "1002771",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/eris-lifesciences-1002771"
  },
  "announcements": [
    {
      "caption": "Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD",
      "datetime": "08-Jun-2026",
      "details": "As Attached",
      "source": "BSE"
    },
    {
      "caption": "Imposition Of Fine By BSE Limited And National Stock Exchange Of India Limited",
      "datetime": "28-May-2026",
      "details": "As Attached",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "27-May-2026",
      "details": "As Attached",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "ERIS Lifesciences Ltd has declared <strong>721%</strong> dividend, ex-date: 29 May 26",
          "dt": "2026-05-29",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

ERIS Lifesciences Ltd Reports Strong Quarterly Upswing Amid Positive Financial Trend

2026-05-21 08:00:20

ERIS Lifesciences Ltd has demonstrated a marked improvement in its financial performance for the quarter ended March 2026, signalling a positive shift in its financial trend after a period of stagnation. The company’s latest quarterly results reveal robust revenue growth, margin expansion, and significant profitability gains, positioning it favourably within the Pharmaceuticals & Biotechnology sector.

ERIS Lifesciences Ltd Surges 8.32% to Day's High of Rs 1458 — Outperforms Sector by 8.15 Percentage Points

2026-05-20 15:01:22

The Sensex edged up 0.26% after a volatile session, but ERIS Lifesciences Ltd outpaced the broader market with an 8.32% gain, reaching an intraday high of Rs 1458. This 8.15-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

ERIS Lifesciences Ltd is Rated Sell

2026-05-20 10:10:56

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

ERIS Lifesciences Ltd is Rated Sell

2026-05-09 10:10:36

ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

ERIS Lifesciences Ltd Valuation Shifts Signal Growing Price Pressure Amid Sector Comparisons

2026-05-05 08:01:25

ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change has prompted a downgrade in its Mojo Grade from Hold to Sell, signalling increased caution among investors despite the company’s solid operational metrics and long-term returns outperforming the Sensex.

ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-04-29 08:00:46

ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, signalling improved price attractiveness for investors. Despite recent headwinds reflected in its share price performance, the company’s relative valuation metrics now present a more balanced risk-reward profile compared to its pharmaceutical peers and historical averages.

ERIS Lifesciences Ltd is Rated Sell

2026-04-28 10:10:55

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with the latest insights into its performance and outlook.

ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-04-24 08:03:17

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, as reflected in recent indicator readings. Despite a 3.07% gain on 24 Apr 2026, the stock’s technical parameters present a complex picture, with mixed signals from MACD, RSI, moving averages, and other key indicators, suggesting cautious optimism amid underlying challenges.

ERIS Lifesciences Ltd is Rated Sell

2026-04-17 10:10:58

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

View All News